跳转至内容
Merck
  • Focal rituximab-induced edematous reaction at primary cutaneous follicle center lymphoma lesions: case report and literature review.

Focal rituximab-induced edematous reaction at primary cutaneous follicle center lymphoma lesions: case report and literature review.

Dermatology (Basel, Switzerland) (2011-10-12)
F Brunet-Possenti, N Franck, J Tamburini, S Jacobelli, M-F Avril, N Dupin
摘要

Primary cutaneous follicle center lymphoma (PCFCL) is the most common cutaneous B cell lymphoma. It is most often indolent and responds well to rituximab. We present a case of transient rituximab-induced edematous lesions located exclusively on tumor papules in a patient treated for PCFCL. Based on this observation and on a review of the literature, we discuss the mechanism of this edematous reaction which does not seem to be allergic. Indeed, this focal reaction observed solely during the first infusion of rituximab is more likely linked with local cytokine release induced by B cell lysis in the skin. This reaction is neither unusual nor severe and should not lead to an interruption of rituximab.

材料
货号
品牌
产品描述

Supelco
马来酸氯苯那敏, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
(±)-氯苯那敏 马来酸盐, ≥99% (perchloric acid titration)
Sigma-Aldrich
S-(+)-Chlorpheniramine maleate salt
Supelco
扑尔敏马来酸盐标准液 马来酸盐 溶液, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
氯苯那敏, European Pharmacopoeia (EP) Reference Standard
马来酸右氯苯那敏, European Pharmacopoeia (EP) Reference Standard